1.  A Phase II, Multi-Center, Randomized, Double-Blind Parallel Group, Placebo-Controlled Study to Assess the Clinical Benefit and Safety of Droxidopa in Patients with Intradialytic Hypotension.

 

2.  The Effect of Liraglutide Compared to Sitagliptin, both in Combination with Metformin in Subjects with Type 2 Diabetes

 

3.  A Multi-Center, Randomized, Open-Label, Active-Comparator Controlled Study to Assess the Efficacy, Safety and Tolerability of Taspoglutide Compared to Exenatide in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin, Thiazolidinedione or a Combination of Both.

 

4.  A Double-Blind, Dose-Ranging, Placebo-Controlled, Randomized Study to Evaluate the Safety and Efficacy of INCBO13739 plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetic Subjects not Adequately Controlled by Metformin Monotherapy

 

5.  Outcome Trial Evaluating the Efficacy and Safety of  Norditropin in Adulat Patients on Chronic Hemodialysis

 

6.  A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of AST-120 for Prevention of Chronic Kidney Disease Progressioin in Patients with Moderate to Severe Chronic Kidney Disease.

 

7.  A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Withdrawal Study Comparing MCI-196 Versus Placebo Following a 12 Week Dose Titration Period with MCI-196 in Chronic Kidney Disease with Hyperphosphatemia.

 

8.  A Phase IV, Long-Term, Observational Safety Study in End Stage Renal Disease Subjects Tretaed with Lanthanum Carbonate

 

9.  Evaluation of Cinacalcet HCL Therapy to Lower Cardiovascular Events

 

10.  A Randomized, Open-Label, Multicenter Study of Epoetin Alfa Comparing Two Extended-Dosing Regimens, Once-Weekly and Every-Two-Weeks, With the Three-Times-Weekly dosing Regimen for Initiation and Maintenance Treatment in Anemic Subjects with Chronic Kidney Disease

 

11.  Lixivaptan versus Placeba in the Treatment of Hyponatremia:  A Randomized, Double-Blind Trial in Euvolemic Subjects with Hypnatremia.

 

12.   A Phase III, Double-Blind, Randomized Placebo-Controlled Study, to Evaluate the Effects of RO4607381 on Cardiovascular Risk in Stable CHD Patients with a Documented Recent Acute Coronary Syndrome

 

13.  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, safety and Tolerability of Taspoglutide Compared to Placebo in Obese patients with Type 2 Diabetes mellitus Inadequately Controlled with Metformin Monotherapy.

 

 

 

 

 

1. Efficacy of XXX Drug Compared to Placeb in Inducing and Maintainig Weight Loss in Overweight or Obese Subjects with Type 2 Diabetes after 52 Weeks. CLOSED

 

2.  Comparison of the Change in HbA1c and the Safety of Bedford Laboratories 70/30 (Biphasic) 100 IU/ml rh-Insulin and Novo Nordisk Novolin 70/30 rh-Insulin in Subjects with Type 1 and Type 2 Diabetes  DELAYED

 

3.  An 8 Week Randomized, Double-Blind Parallel Group, Multicenter, Forced Titration Study to Evaluate the Efficacy and Safety of Aliskiren plus HCTZ versus Aliskiren Monotherapy in Metabolic Syndrome Patients with Stage 2 Hypertension....CLOSED

 

4.  An 8 Week Multicenter, Randomized, Double-Blind, Active Control, Parallel Group, Forced Titration Study to Evaluate the Efficacy and Safety of Alikerin/Amlodipine/Hctz Compared to Alikerin/Amlodipine in non-Caucasian Patients with Stage 2 Hypertension CLOSED

 

For Information Regarding Our New Exciting Clinical Trials in Diabetes, Heart Disease, and Chronic Kidney Disease, Please Visit:

 

 Diabetes and Chronic Kidney Disease

Hyponatremia (low sodium)

Hypertension

Chronic Kidney Disease, Hyperphosphatemia